Su, Wei-Wen
National Taiwan University Hospital
4 papers on CoChatORCID 0000-0001-5554-5938
Most cited papers
- Verified
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 746
- Verified
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 545
- Verified
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Harrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 497
- Verified
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
Tsai, P.-C., Kuo, H.-T., Hung, C.-H., Tseng, K.-C., Lai, H.-C., Peng, C.-Y., Wang, J.-H., Chen, J.-J., Lee, P.-L., Chien, R.-N., et al. (2023) · Journal of Hepatology
Metabolism, Diabetes, and CancerHepatitis C virus research
Cited by 82
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free